VIRTUALDUB 1.10.4 ENTRY POINT NOT FOUND FREE

Furthermore, none of the reported micro/nanobot system has demonstrated practically useful speed high enough for biomedical applications due to high-speed blood flow in human arteries (dimensions from 4 to 25 mm) with a blood flow velocity from 100 to 400 mm/s 20. However, designing nanobots for biological functionality is still a challenge as they have some inherent limitations, such as complex preparation technology, difficulty of surface modification, difficulty of motion in biological fluids and depending on the material, poor biocompatibility or biodegradability 6, 18, 19. Chemically propelled micro-/nanorobots have been widely explored for active drug delivery, and tremendous progresses has been made in the past few years 17. Micro/nanomotors with efficient cargo towing and effective penetrating abilities make them excellent delivery vehicles that can meet the necessary features for targeted delivery of therapeutics 6. Hence, for targeted anticancer delivery of therapeutic payloads to disease sites, drug carriers are desired to possess some distinctive traits, including self-propelling force and velocity, navigational functions, precise cell targeting, drug cargo-towing and finally tissue penetration with the release of drug payload 12– 16. Furthermore, despite surface functionalization with a specific ligand that allows nanocarriers to increase the active targeting ability the nanocarriers are unable to guide themselves to a target. Existing anticancer drug delivery systems demonstrate pharmacokinetic (PK) limitations as they are passive systems driven by the blood fluidics and lack intrinsic navigation for long circulation time, targeting, localized delivery, and tissue penetration 10, 11. Miniature robotic systems provide considerable benefits over conventional and micro/nanoparticle-based therapies 8, 9. The multicomponent nanobot’s design represents a more pronounced method in targeting tumors with self-assisted anticancer drug delivery for ‘far-reaching’ sites in treating cancers.ĭesigning miniaturized and versatile robots in the dimensional-range of a few micrometers or less offer potential for unprecedented biomedical applications, such as refinements in targeted drug delivery platforms 1– 7.

VIRTUALDUB 1.10.4 ENTRY POINT NOT FOUND FREE

Further, nanobot reduce ex vivo HCT116 tumor spheroids more efficiently than free DOX. In addition, the nanobots preferably release DOX in the intracellular lysosomal compartment of human colorectal carcinoma (HCT116) cells by the opening of Fe 3O 4 NP gate. The nanobots propel at high velocities even in complex biological fluids. Autonomous propulsion of the nanobots and their external magnetic guidance is enabled by enriching Fe 3O 4 NPs with dual catalytic-magnetic functionality. Here, multi-component magnetic nanobot designed by chemically conjugating magnetic Fe 3O 4 nanoparticles (NPs), anti-epithelial cell adhesion molecule antibody (anti-EpCAM mAb) to multi-walled carbon nanotubes (CNT) loaded with an anticancer drug, doxorubicin hydrochloride (DOX) is reported. Self-propelling magnetic nanorobots capable of intrinsic-navigation in biological fluids with enhanced pharmacokinetics and deeper tissue penetration implicates promising strategy in targeted cancer therapy. The multicomponent nanobot's design represents a more pronounced method in targeting tumors with self-assisted anticancer drug delivery for 'far-reaching' sites in treating cancers. In addition, the nanobots preferably release DOX in the intracellular lysosomal compartment of human colorectal carcinoma (HCT116) cells by the opening of Fe3O4 NP gate. Autonomous propulsion of the nanobots and their external magnetic guidance is enabled by enriching Fe3O4 NPs with dual catalytic-magnetic functionality. Here, multi-component magnetic nanobot designed by chemically conjugating magnetic Fe3O4 nanoparticles (NPs), anti-epithelial cell adhesion molecule antibody (anti-EpCAM mAb) to multi-walled carbon nanotubes (CNT) loaded with an anticancer drug, doxorubicin hydrochloride (DOX) is reported.

Virtualdub 1.10.4 entry point not found